-
Jiangsu Hengrui Medicine’s SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that the National Medical Products Administration (NMPA) has accepted for review its market filing for SHR-1701 in combination with fluorouracil and platinum for the first-line treatment of locally advanced unresectable, recurrent, or metastatic adenocarcinoma of…
-
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
•
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute Co., Ltd, has entered into a strategic partnership with Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Gilead’s subsidiary Kite Pharma. The collaboration…
-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced the appointment of Dr. Liu Yongjun as its Group CEO and Global R&D President. Dr. Liu will be responsible for leading the company’s research and development, pipeline strategy, and global business development initiatives. Dr. Liu…
-
Sinopharm Holding Appoints New Chairman and President Following Leadership Changes
•
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of its board of directors for the appointment of Zhao Bingxiang as the new chairman and Lian Wanyong as the president. This comes as former chairman Yu Qingming and president Liu Yong have stepped down from…
-
China’s NMPA Releases Standards for Brain-Computer Interface Medical Devices
•
The National Medical Products Administration (NMPA) in China has issued a notification confirming the establishment of two new standards related to medical devices utilizing Brain-Computer Interface (BCI) technology. The first standard, titled “Terminology and Definitions for Medical Devices Using Brain Computer Interface (BCI) Technology,” aims to provide a clear framework…
-
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first half of 2024, reporting a 32.2% year-on-year (YOY) increase in revenues to RMB 1.383 billion, which includes a USD 90 million cooperation payment from its U.S. partner Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK),.…
-
Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine H1 receptor-targeted drug Zerviate (OT-1001) has been granted marketing approval in China with priority review status. The drug is indicated for the treatment of itching symptoms associated with allergic conjunctivitis. Zerviate, originally developed by the…
